Adc Therapeutics Sa Stock Price, News & Analysis

PharmaVentures has announced the opening of a new office in Seoul, South Korea, as part of its strategic expansion to support Korean biopharma companies. JungHyun Eom will be based in Seoul, enhancing the firm's engagement with the rapidly growing Korean biotech sector. With over 30 years of experience, PharmaVentures has successfully facilitated over 40 transactions linking Western pharma with Korean innovators. The firm also collaborates with Korean government institutions and financial groups to bolster the global presence of the Korean biopharma industry.

ADC Therapeutics (NYSE: ADCT) has filed its Annual Report on Form 20-F with the SEC for the fiscal year ending December 31, 2022. This report is accessible on the SEC's website and the company's investor site. ADC Therapeutics is focused on advancing targeted antibody drug conjugates (ADCs), particularly ZYNLONTA, which is FDA-approved for treating relapsed or refractory diffuse large B-cell lymphoma. The company is also developing multiple ADCs in clinical and preclinical phases. Looking ahead, forward-looking statements highlight potential risks, including achieving sales guidance and managing operational expenses.

ADC Therapeutics (NYSE: ADCT) will have its CEO Ameet Mallik present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 7, 2023, at 2:50 p.m. ET. The presentation will be available via a live webcast on the company’s Investors page, with a replay accessible for 30 days afterwards.

ADC Therapeutics focuses on developing next-generation, targeted antibody drug conjugates for cancer treatment. Their CD19-directed ADC, ZYNLONTA, is FDA-approved for relapsed or refractory diffuse large B-cell lymphoma. The company is based in Lausanne, Switzerland, with operations in various locations including London and San Francisco.

ADC Therapeutics reported Q4 2022 net sales of $19.8 million for ZYNLONTA, a 16.5% increase year-over-year, and $74.9 million for the full year 2022. The company anticipates double-digit growth in net sales for FY 2023, with a potential revenue increase of $500 million to $1 billion in the future.

The cash runway is expected to extend into mid-2025. The company also announced milestones for pipeline developments and new leadership appointments. Net loss improved to $24.2 million in Q4 2022, a reduction from $34.4 million in Q4 2021, attributed to higher revenues and reduced operating expenses.

ADC Therapeutics (NYSE: ADCT) announced a conference call scheduled for February 28, 2023, at 8:30 a.m. ET to discuss its Q4 and year-end 2022 financial results and recent business updates. The call can be accessed via a registration link provided in the release, with a live webcast available on the company's investor relations website. ADC Therapeutics, based in Lausanne, Switzerland, focuses on improving cancer treatment through its proprietary antibody drug conjugates. The FDA has approved their product, ZYNLONTA, for certain types of lymphomas, and the company is advancing multiple ADCs in clinical development.